Sironax

Sironax is an emerging leader in the discovery and development of transformational therapies that address degenerative diseases affecting longevity, diseases requiring supportive care, and certain rare diseases. The company focuses on mental decline (neurodegeneration) and physical decline (muscular disorders) by targeting three core drivers: dysregulated cell death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax's breakthrough pipeline contains multiple first-in-class and/or potentially best-in-class programs, among which three have entered into clinical stage. Each of these programs demonstrates Sironax’s unique biological insights and mechanistic innovations, with research focus spanning neuroinflammation, axonal degeneration, muscular weakness, epithelial cell death, and metabolic disorders. All these clinical assets at Sironax are de novo designed and synthesized within the company, each of which features distinct chemical scaffold. In parallel to the actively ongoing clinical development, the company also continues to expand its discovery footprint and plans to advance additional programs into the clinic over the next few years. With operations in the U.S., China, Switzerland, and Australia, Sironax presently has 160 employees and is growing. We continue to build our global team of highly skilled chemists, biologists, and clinicians. Along with decades of experience in global pharmaceutical R&D, our team shares a collective vision of shifting the treatment paradigm for degenerative diseases affecting longevity to ultimately improve the lives of millions of patients and their families around the world.